| Autor: |
Jaime L. Schneider, Alona Muzikansky, Jessica J. Lin, Elizabeth A. Krueger, Inga T. Lennes, Joseph O. Jacobson, Michael Cheng, Rebecca S. Heist, Zofia Piotrowska, Justin F. Gainor, Alice T. Shaw, Ibiayi Dagogo-Jack |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JTO Clinical and Research Reports. 3:100347 |
| ISSN: |
2666-3643 |
| Popis: |
The central nervous system (CNS) is a common site of progression among patients withPatients with metastaticA total of 16 patients were enrolled between November 2016 and January 2019. Nine patients (56%) had received prior CNS radiation, with a median of 10.9 months between radiation and lorlatinib. At 12 weeks, the intracranial disease control rate was 100% and intracranial objective response rate was 87%. While on study, the complee intracranial response rate was 60%. With median follow-up of 22 months, seven patients experienced disease progression, including five patients with CNS relapse. The median intracranial and extracranial progression-free survivals were 38.8 months (95% confidence interval: 16.9-not reported) and 41.1 months (95% confidence interval: 17.6-not reported), respectively. Molecular analysis of plasma or tissue from patients with extracranial progression on lorlatinib revealedLorlatinib induced durable intracranial responses in patients with |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
